Monalisa모나리자

Monalisa is a small tissue and hygiene maker whose profits have shrunk sharply, with the share price down about 41% over the past year.

Monalisa makes tissue paper and hygiene products in Korea, sold through domestic distribution channels. Trailing twelve-month revenue is about ₩129B with an operating margin of only 1.3%, and the company holds ₩15.7B in cash with no borrowings reported. The share price is ₩1,388, roughly ₩51B in market value, well below its 52-week high of ₩2,695.

What stands out

• Revenue has been broadly flat to slightly down since 2023, while operating income fell from ₩6.5B in 2023 to ₩0.3B in 2025 and recovered only modestly to ₩1.7B on a trailing basis to H1 2026.
• Net income is above operating income on a trailing basis, which suggests non-operating items contributed to profit; the data does not explain the source.
• The balance sheet looks conservative: liabilities are 19.5% of equity, cash is ₩15.7B and borrowings are reported as null, meaning none were listed in the data.
• Valuation metrics are mixed: trailing P/E is 23.9 and P/B is 0.6, and the dividend yield is 3.6%, but the company's earnings have been volatile year to year.
• Foreign ownership rose from 1.4% to 2%, while foreign investors were net sellers over the last 20 days; the data includes no analyst views or news headlines.

What to watch

• The full-year 2026 results and the next quarterly report, to see whether the margin recovery holds.
• Follow-up on the corporate value-up plan announced in April 2026 and any further shareholder-return measures.
• The internal DCF fair value range is wide (₩106 to ₩2,395, base ₩902), so the outcome depends heavily on assumptions about future profitability.